Federal Officials Take a Step Back on Psychedelic Ban: Easing Restrictions for Medical Research In a significant shift in policy, the federal government is reconsidering its strict stance on psychedelics, including ibogaine, a plant-based substance that has shown promise in treating severe depression and other mental health conditions. Currently classified as Schedule I substances, the most restrictive category for illicit drugs, ibogaine and similar psychedelics have been largely off-limits to researchers seeking to explore their potential medical benefits. However, the administration's latest move aims to ease these restrictions, paving the way for scientists to conduct further studies on the therapeutic applications of these substances. As researchers continue to uncover the potential of psychedelics in treating a range of conditions, this policy change could mark a significant turning point in the field.
Ibogaine and other psychedelics remain banned under the federal government's most restrictive category for illegal, high-risk drugs. But the administration is taking steps to ease restrictions and spur research on using the drugs for medical purposes, including conditions like severe depression.
